期刊
SCIENCE
卷 372, 期 6549, 页码 1418-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abh1282
关键词
-
资金
- Goldman Sachs
- Citadel
- Citadel Securities
- Guy Foundation
- GW Pharmaceuticals
- Kusuma Trust
- Jagclif Charitable Trust
- UCLH Charity
- MRC [MR/S019553/1, MR/R02622X/1, MR/V036939/1]
- NIHR Imperial Biomedical Research Centre (BRC):ITMAT
- Cystic Fibrosis Trust SRC [2019SRC015]
- Horizon 2020 Marie Sklodowska-Curie Innovative Training Network (ITN) European Training Network [860325]
- Rosetrees Trust
- John Black Charitable Foundation
- Medical College of St Bartholomew's Hospital Trust
- University College London Hospitals (UCLH)
- Barts NIHR Biomedical Research Centres
- British Heart Foundation (BHF) Accelerator Award [AA/18/6/34223]
- BHF Intermediate Research Fellowship [FS/19/35/34374]
- Wellcome Trust [207511/Z/17/Z, 214191/Z/18/Z]
- NIHR Biomedical Research Funding
- UKRI/NIHR UK-CIC
- CRUK Immunology grant [26603]
- UKRI/MRC COVID-19 Rapid response grant [COV0331 MR/V027883/1]
- MRC [MR/V036939/1, MR/S019553/1, MR/R02622X/1] Funding Source: UKRI
Vaccination with a single dose of BNT162b2 after prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. In contrast, individuals without prior infection showed reduced immunity against variants after receiving a single vaccine dose.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided with the spread of variants of concern. We investigated whether single-dose vaccination, with or without prior infection, confers cross-protective immunity to variants. We analyzed T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated, or unchanged T cell responses, depending on human leukocyte antigen (HLA) polymorphisms. Single-dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据